Abstract
Changes in smoking habits in the UK and other Western communities are resulting in a decline in the incidence of lung cancer among men in recent years. In women it is still increasing (for the same reason). In many parts of the developing world tobacco consumption is growing, and an epidemic of lung cancer, similar to the one which affected Europe and North America in the second half of this century, will doubtless follow. There is little evidence that political intervention, on the scale required, will significantly influence these trends. So lung cancer is destined to remain the biggest cancer problem worldwide for the foreseeable future, with moe than half a million new cases diagnosed annually [1]. Approximately 80% of these tumours are of non-small cell histological type, including squamous, adeno- and large cell carcinomas.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Parkin DM, Saxo AJ (1993) Lung cancer: worldwide variation in occurrence and proportion attributed to tobacco use. Lung Cancer (suppl) 9:1–16.
Squires TS, Tong T (1993) Cancer statistics. CA Cancer J Clin 43:7–26.
Rudd R (1991) Chemotherapy in the treatment of non-small cell lung cancer. Resp Dis Prac 7:12–15.
Berry RJ, Laing AH, Newman CR, Peto J (1977) The role of radiotherapy in treatment of inoperable lung cancer. Int J Radiat Oncol Biol Phys 2:433–439.
Roswit B, Patno ME, Rapp R et al. (1968) The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology 90:688–697.
Johnson DH, Einhorn LH, Bartolucci A et al. (1990) Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 113:33–38.
Perez CA, Pajak TF, Rubin P et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59:1874–1881.
Einhorn LH, Loehrer PJ, Williams SD et al. (1986) Random prospective study of vindesine versus vindesin plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol 4:1037–1043.
Kris M, Cohen E, Gralla R (1985) An analysis of 134 phase II trials in non-small cell lung cancer (NSCLC) (Abstr). Proc of the IV World Conf on Lung Cancer, Toronto, 4:39.
Cullen MH (1983) Acceptable damage to normal tissue. In: Stoll B (ed) Cancer treatment: end-point evaluation. Wiley, Chichester, 139–171.
Watanabe Y, Shimizu J, Oda M et al. (1991) Aggressive surgical intervention in N2 non-small cell cancer of the lung. Ann Thorac Surg 51:253–261.
Martini N, Flehinger BJ (1987) The role of surgery in N2 lung cancer. Surg Clin North Am 67:1037–1049.
Mountain CF (1990) Expanded possibilities for surgical treatment of lung cancer: survival in stage IIIA disease. Chest 97:1045–1051.
Naruke T, Goya T, Tsuchyia R, Suemasu K (1988) The importance of surgery to nonsmall cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg 46:603–610.
Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A, Canela M, Ariza A, Skacel Z, Morera-Prat J, Abad A (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153–158.
Roth JA, Fosella F, Komaki R, Ryan MB, Putnam JB, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, Atkinson EN, Hong WK (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage III non-small cell lung cancer. J Natl Cancer Inst 86:673–680.
Peto R (1987) Why do we need systematic overviews of randomised trials? Stat Med 6:233–240.
Stewart LA, Pignon JP, Parmar MKB, Arriagada R, Souhami RL on behalf of the NSCLC Collaborative Group (1994) A meta-analysis of adjuvant chemotherapy in non-small cell lung cancer (NSCLC) using updated individual patient data. Lung Cancer II (suppl 2): 49–50.
Cullen MH, Joshi R, Chetiyawardana AD, Woodroffe CM (1988) Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 58:359–361.
Cullen MH (1994) Trials of radical radiotherapy versus chemotherapy plus radical radiotherapy in non-small cell lung cancer. Semin Oncol 21(3 suppl 4):34–41.
Schaake-Koning C, Van Den Bogaert W, Dalesio O et al. (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326(8):524–530.
Le Chevalier T, Arriagada R, Quoix E et al. (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. J Natl Cancer Inst 83:417–423.
Le Chevalier T, Arriagada R, Quoix E et al. (1991) Impact of chemotherapy (CT) on survival of locally advanced non-small-cell lung cancer (NSCLC): results of a randomized study in 353 pts (Abstr). Lung Cancer 7(suppl):159.
Dillman RO, Seagren SL, Propert KJ et al. (1990) A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 323:940–945.
Souhami RL, Spiro SG, Cullen MH (1991) Chemotherapy and radiation therapy as compared with radiation therapy in stage III non-small-cell cancer. N Engl J Med 324:1136.
Sause W, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran W, Byhardt R, Fisher G, Turrisi A (1994) RTOG 8808 ECOG 4588, preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer. Lung Cancer II (suppl 1):179.
Arriagada R, Stewart LA, Pignon JP, Souhami RL, LeChevalier T on behalf of the NSCLC Collaborators Group (NSCLCCG) (1994) Combined radio-chemotherapy in the management of locally advanced non-small cell lung cancer (NSCLC). Lung Cancer II (suppl 2):146–147.
Souhami RL, Stewart LA, Arriagada R, Parmar MKB, Le Chevalier T, Pignon JP (1994) A data-based meta-analysis of randomised trials of chemotherapy versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC). Lung Cancer II (suppl 2):24–25.
Slevin, M, Stubbs L, Plant HJ, et al. (1990) Attitudes to chemotherapy, comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med J 300:1458–1460.
Hardy JR, Noble T, Smith IE (1989) Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer 60:764–766.
Green MR (1991) Unresectable stage III non-small-cell lung cancer: lessons and directions from clinical trials research. J Natl Cancer Inst 83:382.
Cullen MH, Billingham LJ, Dunn J (1997) Abstract 8. Lung Cancer 18 (suppl 1):4.
Cullen MH, Billingham LJ, Woodroffe CM, Gower N, Souhami RL, Chetiyawardana AD, Joshi R, Rudd R, Trask C, Spiro S (1997) Abstract 10. Lung Cancer 18 (suppl 1):5.
Cullen MH, Woodroffe CM, Billingham LJ, Chetiyawardana AD, Joshi R, Ferry D, Connolly CK, Bessell E (1997) Abstract 11. Lung Cancer 18 (suppl 1):5.
Billingham LJ, Cullen MH, Woods BW, Chetiyawardana AD, Joshi R, Cook J, Woodroffe CM (1997) Abstract 26. Lung Cancer 18 (suppl 1):9.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag London Limited
About this chapter
Cite this chapter
Cullen, M.H. (1998). Non-Curative Chemotherapy for Non-Small Cell Lung Carcinoma. In: Slevin, M.L., Tate, T. (eds) Cancer: How Worthwhile is Non-Curative Treatment?. Focus on Cancer. Springer, London. https://doi.org/10.1007/978-1-4471-1509-0_16
Download citation
DOI: https://doi.org/10.1007/978-1-4471-1509-0_16
Publisher Name: Springer, London
Print ISBN: 978-3-540-76083-2
Online ISBN: 978-1-4471-1509-0
eBook Packages: Springer Book Archive